Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(33.3%)

Phase 2

2(22.2%)

Phase 1

2(22.2%)

N/A

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 4(3)

Phase 2(2)

Phase 1(2)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01003483Phase 2Completed

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients

Role: lead

NCT00823004Phase 1Completed

Antagonist/Letrozole in Poor Responders

Role: lead

NCT00846183Phase 2Completed

Effect of Local Injury on Implantation

Role: lead

NCT01214772Phase 4Completed

The Effect of Heparin in Treatment IVF-ET Failure

Role: collaborator

NCT01213147Phase 4Completed

Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders

Role: collaborator

NCT00823121Phase 1Unknown

Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification

Role: lead

NCT00837733Not ApplicableCompleted

Endometrial Local Injury and Implantation Failure

Role: lead

NCT00830492Phase 4Completed

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Role: lead

NCT00823602Phase 3Unknown

Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH

Role: lead

All 9 trials loaded